Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob smith who wrote (11991)	12/2/1997 4:25:00 PM
From: Henry Niman	Respond to of 32384

bob, Actually, LGND began that day at 13 1/8 so we have already run past that number and the initila "Breakout" post highlights how cheap LGND is today. A short while ago they set a 52-week high of 18 3/8 and I expect a quick move back to that level. LGND's fundatmentals are much stronger than they were 14 months ago (when they announced the initial animal data on Targretin for prevention of diabetes and breast cancer) and now they have compelling clinicals on Panretin and Targretin, and a LLY compound waiting in the wings. The pipeline is the best in the business and today's news on AGPH shows what can happen to those "experimental" programs. LGND's technology is at the heart of pharma and Biotech drug therapeutics, and they know it. The street has always been a bit slow on the pickup when it comes to cutting edge technology, and LGND's current price is an excellent example.